Under the agreement, NuvoBio will use its platform to generate peptide candidates against therapeutic targets designated by Protagonist. Protagonist will have the exclusive right to develop and commercialize compounds arising from the collaboration.
Under the agreement, NuvoBio will use its platform to generate peptide candidates against therapeutic targets designated by Protagonist. Protagonist will have the exclusive right to develop and commercialize compounds arising from the collaboration.
Yellowbird Diagnostics Inc. today announced the successful dosing and imaging of the first participants in its Phase I clinical trial of NeuCaVis™, a novel metabolic PET imaging agent designed to enable precise visualization of inflammation.
NuvoBio, a CBV SUMMIT level company, has been selected for the prestigious MDSS accelerator program. A one of only 12 startups chosen across North America, NuvoBio is redefining peptide discovery with DarwinAI.
Developed in-house, the platform simultaneously identifies effective binders and screens for off-target effects, effectively de-risking candidates early to ensure safer, more effective therapeutics.
Congratulations to our ASCENT Virtual Pitch Event winner, CEREBRO Therapeutics Inc., led by Martin Levesque!
Earlier today, we had the privilege of
watching our nine ASCENT companies deliver high-impact virtual pitches to a panel of distinguished judges from …
We’re excited to announce our upcoming Virtual Pitch Competition as part of the CBV ASCENT Program!
Nine high-potential companies from our current cohort will take the virtual stage to pitch their ventures and compete for a coveted pitch prize. These founders are building bold solutions across…
Capital BioVentures (CBV), a leading biotech accelerator, dedicated to supporting the growth of early-stage life sciences companies, is proud to announce the launch of its newest offering, the ASCENT Program…
The Stem Cell Network (SCN) and Capital BioVentures (CBV) are pleased to announce a new partnership to accelerate the development and commercialization of regenerative medicine innovations…
Capital BioVentures (CBV), Ottawa’s Biotech Accelerator Program, proudly announces the first cohort of companies selected for its support programming. Seven innovative enterprises have been chosen…
Congratulations to our ASCENT Virtual Pitch Event winner, CEREBRO Therapeutics Inc., led by Martin Levesque!
Earlier today, we had the privilege of
watching our nine ASCENT companies deliver high-impact virtual pitches to a panel of distinguished judges from …
We’re excited to announce our upcoming Virtual Pitch Competition as part of the CBV ASCENT Program!
Nine high-potential companies from our current cohort will take the virtual stage to pitch their ventures and compete for a coveted pitch prize. These founders are building bold solutions across…
Capital BioVentures (CBV), a leading biotech accelerator, dedicated to supporting the growth of early-stage life sciences companies, is proud to announce the launch of its newest offering, the ASCENT Program…
The Stem Cell Network (SCN) and Capital BioVentures (CBV) are pleased to announce a new partnership to accelerate the development and commercialization of regenerative medicine innovations…
Capital BioVentures (CBV), Ottawa’s Biotech Accelerator Program, proudly announces the first cohort of companies selected for its support programming. Seven innovative enterprises have been chosen…
An organization aimed at incubating Ottawa biotechnology startups says it’s poised to help several promising companies commercialize their products after securing a multimillion-dollar grant from the federal government…
Under the agreement, NuvoBio will use its platform to generate peptide candidates against therapeutic targets designated by Protagonist. Protagonist will have the exclusive right to develop and commercialize compounds arising from the collaboration.
Yellowbird Diagnostics Inc. today announced the successful dosing and imaging of the first participants in its Phase I clinical trial of NeuCaVis™, a novel metabolic PET imaging agent designed to enable precise visualization of inflammation.
NuvoBio, a CBV SUMMIT level company, has been selected for the prestigious MDSS accelerator program. A one of only 12 startups chosen across North America, NuvoBio is redefining peptide discovery with DarwinAI.
Developed in-house, the platform simultaneously identifies effective binders and screens for off-target effects, effectively de-risking candidates early to ensure safer, more effective therapeutics.
